Dekabank Deutsche Girozentrale Reduces $1M in Beam Therapeutics Inc. ($BEAM)
Key Points
- Dekabank Deutsche Girozentrale changed its Beam Therapeutics Inc. ($BEAM) stake by 100.0% last quarter, cutting to 0 shares.
- Wall Street's consensus rating on $BEAM is Strong Buy and an average price target of $51.07.
- $BEAM last traded around $29.41.
Dekabank Deutsche Girozentrale reduced its position in Beam Therapeutics Inc. ($BEAM), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Beam Therapeutics Inc. after selling 50,000 shares during the quarter.
Beam Therapeutics Inc. ($BEAM) Stock
Beam Therapeutics Inc. Earnings
Analysts Set New Price Targets
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.